Lupin Introduces Ganirelix Acetate Injection in US

Lupine Limited (Lupin), a global pharmaceutical company, announced the launch of Ganirelix Acetate Injection, 250 mcg / 0.5 mL, single-dose prefilled syringe, approved by the United States Food and Drug Administration (FDA).

Ganirelix Acetate Injection, 250 mcg / 0.5 mL, Single Dose Prefilled Syringe is the exact equivalent of Organon USA LLC's Reference Listed Drug (RLD), Ganirelix Acetate Injection, 250 mcg / 0, 5 ml. It is used to suppress the luteinizing hormone (LH) surge in women with ovarian hyper stimulation.

Annual sales of ganirelix acetate injection are estimated at $87 million (IQVIA MAT December 2023).

Lupine is a new multinational pharmaceutical company based in Mumbai, India. The company develops and markets various brands and formulations, biotech products and APIs in more than 100 markets in the US, India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe and other regions. Middle East Region.

Lupine Limited is an Indian pharmaceutical company headquartered in Mumbai. The company is one of the largest pharmaceutical companies in the world by product. The company's main focuses are pediatrics, cardiovascular, anti-infectives, diabetes, asthma and tuberculosis.